Kush Bohra's Stock Recommendations: Aurobindo Pharma, KSB, and Hyundai
Kush Bohra's Buy Calls, Target Price, Stop Loss - Auro Pharma, KSB, Hyundai
Ndtv
Image: Ndtv
Technical analyst Kush Bohra has recommended Aurobindo Pharma as a long trade with targets of ₹1,415 and ₹1,480, while setting a stop loss at ₹1,285. He remains bullish on KSB Ltd with targets of ₹920 and ₹945, but advises selling Hyundai with targets of ₹1,760 and ₹1,740.
- 01Aurobindo Pharma is highlighted as a strong long trade with significant upside potential.
- 02KSB Ltd continues to show positive momentum, with revised targets and a higher stop loss.
- 03Hyundai is advised as a sell despite a recent short-covering rally due to low trading volumes.
- 04Bohra's recommendations are based on technical analysis and market trends.
- 05Investors are advised to consult their own financial advisors before making investment decisions.
Advertisement
In-Article Ad
Technical analyst Kush Bohra has provided stock recommendations focusing on three companies. He has identified Aurobindo Pharma as his weekly pick for long trades, setting upside targets at ₹1,415 and ₹1,480, with a stop loss at ₹1,285. Bohra noted a favorable technical structure for Aurobindo, indicating strong momentum. He also reiterated a bullish stance on KSB Ltd, with targets set at ₹920 and ₹945, and a revised stop loss of ₹865, reflecting sustained buying interest. Conversely, he maintained a sell recommendation for Hyundai, targeting ₹1,760 and ₹1,740, while setting a stop loss at ₹1,800. Despite a recent short-covering rally, Bohra expressed concerns about low trading volumes, suggesting that the broader market structure for Hyundai remains bearish.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you agree with Kush Bohra's stock recommendations?
Connecting to poll...
More about Aurobindo Pharma

Aurobindo Pharma Secures USFDA Approval for Cough Relief Suspension
Business Standard • Apr 20, 2026

Aurobindo Pharma Secures USFDA Approval for Glycerol Phenylbutyrate Oral Liquid
Business Standard • Apr 17, 2026

Aurobindo Pharma Secures USFDA Approval for Glycerol Phenylbutyrate Oral Liquid
Business Standard • Apr 17, 2026
Read the original article
Visit the source for the complete story.


